Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Final NIH Policy on the Use of a Single Institutional Review Board for Multisite Research.

Gordon VM, Culp MA, Wolinetz CD.

Clin Transl Sci. 2017 May;10(3):130-132. doi: 10.1111/cts.12447. Epub 2017 Mar 2. No abstract available.

3.

Hemodynamic and symptomatic effects of acute interventions on tilt in patients with postural tachycardia syndrome.

Gordon VM, Opfer-Gehrking TL, Novak V, Low PA.

Clin Auton Res. 2000 Feb;10(1):29-33.

PMID:
10750641
4.

Clostridium septicum alpha toxin uses glycosylphosphatidylinositol-anchored protein receptors.

Gordon VM, Nelson KL, Buckley JT, Stevens VL, Tweten RK, Elwood PC, Leppla SH.

J Biol Chem. 1999 Sep 17;274(38):27274-80.

5.

Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor.

Duesbery NS, Webb CP, Leppla SH, Gordon VM, Klimpel KR, Copeland TD, Ahn NG, Oskarsson MK, Fukasawa K, Paull KD, Vande Woude GF.

Science. 1998 May 1;280(5364):734-7.

6.

Clostridium septicum alpha-toxin is proteolytically activated by furin.

Gordon VM, Benz R, Fujii K, Leppla SH, Tweten RK.

Infect Immun. 1997 Oct;65(10):4130-4.

7.

A role for PACE4 in the proteolytic activation of anthrax toxin protective antigen.

Gordon VM, Rehemtulla A, Leppla SH.

Infect Immun. 1997 Aug;65(8):3370-5.

8.
9.

Family dynamics and children in medical research.

Gordon VM, Bonkovsky FO.

J Clin Ethics. 1996 Winter;7(4):349-54; discussion 362-4. No abstract available.

PMID:
9029336
10.

Vaccination with genetically modified Shiga-like toxin IIe prevents edema disease in swine.

Bosworth BT, Samuel JE, Moon HW, O'Brien AD, Gordon VM, Whipp SC.

Infect Immun. 1996 Jan;64(1):55-60.

11.

In vitro processing of anthrax toxin protective antigen by recombinant PC1 (SPC3) and bovine intermediate lobe secretory vesicle membranes.

Friedman TC, Gordon VM, Leppla SH, Klimpel KR, Birch NP, Loh YP.

Arch Biochem Biophys. 1995 Jan 10;316(1):5-13.

PMID:
7840657
12.

Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases.

Gordon VM, Klimpel KR, Arora N, Henderson MA, Leppla SH.

Infect Immun. 1995 Jan;63(1):82-7.

14.

Proteolytic activation of bacterial toxins: role of bacterial and host cell proteases.

Gordon VM, Leppla SH.

Infect Immun. 1994 Feb;62(2):333-40. Review. No abstract available.

15.

Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice.

Tesh VL, Burris JA, Owens JW, Gordon VM, Wadolkowski EA, O'Brien AD, Samuel JE.

Infect Immun. 1993 Aug;61(8):3392-402.

16.

An enzymatic mutant of Shiga-like toxin II variant is a vaccine candidate for edema disease of swine.

Gordon VM, Whipp SC, Moon HW, O'Brien AD, Samuel JE.

Infect Immun. 1992 Feb;60(2):485-90.

17.

Adenylate cyclase toxin from Bordetella pertussis. Conformational change associated with toxin activity.

Hewlett EL, Gray L, Allietta M, Ehrmann I, Gordon VM, Gray MC.

J Biol Chem. 1991 Sep 15;266(26):17503-8.

18.

Hemolytic activity of adenylate cyclase toxin from Bordetella pertussis.

Ehrmann IE, Gray MC, Gordon VM, Gray LS, Hewlett EL.

FEBS Lett. 1991 Jan 14;278(1):79-83.

19.

Adenylate cyclase toxin from Bordetella pertussis. Identification and purification of the holotoxin molecule.

Hewlett EL, Gordon VM, McCaffery JD, Sutherland WM, Gray MC.

J Biol Chem. 1989 Nov 15;264(32):19379-84.

20.

Adenylate cyclase toxins from Bacillus anthracis and Bordetella pertussis. Different processes for interaction with and entry into target cells.

Gordon VM, Young WW Jr, Lechler SM, Gray MC, Leppla SH, Hewlett EL.

J Biol Chem. 1989 Sep 5;264(25):14792-6.

22.

The origin, basis and nature of medical malpractice liability.

Gordon VM.

Conn Med. 1971 Feb;35(2):73-7. No abstract available.

PMID:
4925960

Supplemental Content

Loading ...
Support Center